World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
59
Citations
14365
World Ranking
3411
National Ranking
88

Laszlo Radvanyi publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Laszlo Radvanyi sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 159 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Laszlo Radvanyi D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Laszlo Radvanyi sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 59 D-Index — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Laszlo Radvanyi is affiliated with the Ontario Institute for Cancer Research in Canada. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, Medicine, and Immunology and Microbiology. Within these main fields, their work is concentrated in the subfields of Immunology, Molecular Biology, Oncology, Cancer Research, and Economics and Econometrics.

Their research topics include:

  • Extracellular vesicles in disease
  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Cancer-related molecular mechanisms research
  • Health Systems, Economic Evaluations, Quality of Life

Recent papers authored or co-authored by Laszlo Radvanyi include:

  • Germline genetic contribution to the immune landscape of cancer, 2021, Immunity
  • Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma, 2022, Cancers
  • Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma, 2021, Journal for ImmunoTherapy of Cancer
  • VISTA expression and patient selection for immune-based anticancer therapy, 2023, Frontiers in Immunology
  • Germline genetic contribution to the immune landscape of cancer, 2020, bioRxiv (Cold Spring Harbor Laboratory)

Frequent co-authors collaborating with Laszlo Radvanyi are:

  • Valentina Evdokimova
  • Hendrik Gassmann
  • Lincoln Stein
  • Stefan Burdach
  • Peter Ruzanov

The scientist has published multiple articles in recognized journals, with notable frequent venues including:

  • Frontiers in Immunology
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Immunity
  • Cancers

Best Publications

  • Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

    Weiyi Peng;Jie Qing Chen;Chengwen Liu;Shruti Malu

  • PD-L1 expression and prognostic impact in glioblastoma.

    Edjah K. Nduom;Jun Wei;Nasser K. Yaghi;Neal Huang

  • Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

    Jason R Westin;Fuliang Chu;Min Zhang;Luis E Fayad

  • PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

    Weiyi Peng;Chengwen Liu;Chunyu Xu;Yanyan Lou

  • Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

    Laszlo G. Radvanyi;Chantale Bernatchez;Minying Zhang;Patricia S. Fox

  • Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

    Yan Lan;Dong Zhang;Chunxiao Xu;Kenneth W. Hance

  • Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3

    Hiroshi Nishina;Klaus D. Fischer;Klaus D. Fischer;Laszlo Radvanyi;Arda Shahinian

  • BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

    Chengwen Liu;Weiyi Peng;Chunyu Xu;Yanyan Lou

  • Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

    Jahan S. Khalili;Shujuan Liu;Tania G. Rodríguez-Cruz;Mayra Whittington

  • Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

    Young Hee Lee;Natalia Martin-Orozco;Natalia Martin-Orozco;Peilin Zheng;Jing Li

  • The IL-2 cytokine family in cancer immunotherapy

    Geok Choo Sim;Laszlo Radvanyi

  • Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

    Richard Wu;Marie Andrée Forget;Jessica Chacon;Jessica Chacon;Chantale Bernatchez

  • IL-2 therapy promotes suppressive ICOS + Treg expansion in melanoma patients

    Geok Choo Sim;Natalia Martin-Orozco;Lei Jin;Yan Yang

  • Rapamycin Enhances Apoptosis and Increases Sensitivity to Cisplatin in Vitro

    Yufang Shi;Andrea Frankel;Laszlo G. Radvanyi;Linda Z. Penn

  • The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer

    Laszlo Radvanyi;Devender Singh-Sandhu;Scott Gallichan;Corey Lovitt

  • CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response

    Laszlo G. Radvanyi;Yufang Shi;Homayoun Vaziri;Ajay Sharma

  • Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers

    Giampaolo Bianchini;Yuan Qi;Ricardo H. Alvarez;Takayuki Iwamoto

  • Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients.

    Feng Wang-Johanning;Laszlo Radvanyi;Kiera Rycaj;Joshua B. Plummer

  • Depressive Symptoms and Cortisol Rhythmicity Predict Survival in Patients with Renal Cell Carcinoma: Role of Inflammatory Signaling

    Lorenzo Cohen;Steven W. Cole;Anil K. Sood;Sarah Prinsloo

  • Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death

    L. G. Radvanyi;Gordon B Mills;R. G. Miller

Frequent Co-Authors

Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Chantale Bernatchez
Chantale Bernatchez The University of Texas MD Anderson Cancer Center
Cara Haymaker
Cara Haymaker The University of Texas MD Anderson Cancer Center
Willem W. Overwijk
Willem W. Overwijk The University of Texas MD Anderson Cancer Center
Michael A. Davies
Michael A. Davies The University of Texas MD Anderson Cancer Center
Jason Roszik
Jason Roszik The University of Texas MD Anderson Cancer Center
Gordon B. Mills
Gordon B. Mills Oregon Health & Science University
Richard G. Miller
Richard G. Miller University of Toronto
Jeffrey E. Gershenwald
Jeffrey E. Gershenwald The University of Texas MD Anderson Cancer Center
Laurence J.N. Cooper
Laurence J.N. Cooper The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology in the USA, exploring related nursing and healthcare degrees can expand career opportunities. Many professionals consider bridging their skills through programs like the fnp to acute care np bridge program to specialize further in patient care with advanced roles.

Accelerated nursing programs offer a fast track for students from non-nursing backgrounds. For example, the accelerated fnp programs allow candidates to become Family Nurse Practitioners more quickly, integrating care skills that complement immunology knowledge.

Similarly, those without prior nursing experience can begin with the best online rn programs for non nurses. These programs provide foundational clinical training and licensure, opening the door to various healthcare professions linked to immunology research and practice.

Lastly, beginners aiming to enter the nursing field might explore the accelerated nursing programs designed for faster admission and completion. These adaptable pathways facilitate quick entry into healthcare roles where immunology expertise is an asset.

Best Scientists Citing Laszlo Radvanyi

Trending Scientists

Recently Published Articles